|32M||10 Mar 2021||United States, New York|
|10M||04 Feb 2021||United States, Boston|
|31M||01 Feb 2021||United States, New York|
|85M||08 Jan 2021||United States, New York|
|105M||06 Jan 2021||United States, South San Francisco|
|135M||08 Dec 2020||United States, New York|
|32M||09 Nov 2020||Singapore, Singapore|
|35M||05 Nov 2020||United States, Emeryville|
|10M||27 Oct 2020||United States, San Francisco|
– Caresyntax, the leading enterprise-level digital surgery platform delivering actionable insights to make surgery smarter and safer, today announced a $30m extension to its Series C funding round. – The round was led by PFM Health Sciences with participation from ProAssurance, Harmonix, and existing investors such as the Relyens Group and IPF Partners. – That round also included investments from Optum Ventures, Intel Capital, Lauxera Capital Partners, Vesalius Biocapital III, Arno Capital, Rezayat Investments, ... Read more
– GenXComm is an Austin TX-based provider of private networking solutions. – Company raised $20M in Series B funding. – The round was led by Motive Companies, with participation from Raine Next-Gen Communications, BMW iVentures, Intel Capital, Azure Capital and Bandgap Ventures. – The company intends to use the funds to accelerate product development and commercial launch of their private 4G LTE and 5G network solutions. Read more
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.